<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">48474</article-id><article-id pub-id-type="doi">10.7554/eLife.48474</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-150811"><name><surname>Thomson</surname><given-names>Benjamin R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6565-5866</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144683"><name><surname>Carota</surname><given-names>Isabel A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7980-2377</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-144684"><name><surname>Souma</surname><given-names>Tomokazu</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3285-8613</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144685"><name><surname>Soman</surname><given-names>Saily</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41846"><name><surname>Vestweber</surname><given-names>Dietmar</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3517-732X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-6599"><name><surname>Quaggin</surname><given-names>Susan E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3706-5727</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><institution content-type="dept">Feinberg School of Medicine</institution>, <institution>Northwestern University</institution>, <addr-line><named-content content-type="city">Chicago</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Vascular Cell Biology</institution>, <institution>Max Planck Institute for Molecular Biomedicine</institution>, <addr-line><named-content content-type="city">Münster</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-17809"><name><surname>Smith</surname><given-names>Lois</given-names></name><role>Reviewing editor</role><aff><institution>Boston Children's Hospital/Harvard Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>quaggin@northwestern.edu</email> (SQ);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>10</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e48474</elocation-id><history><date date-type="received"><day>15</day><month>05</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Thomson et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Thomson et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-48474-v1.pdf"/><abstract><p>Elevated intraocular pressure (IOP) due to insufficient aqueous humor outflow through the trabecular meshwork and Schlemm's canal (SC) is the most important risk factor for glaucoma, a leading cause of blindness worldwide. We previously reported loss of function mutations in the receptor tyrosine kinase TEK or its ligand ANGPT1 cause primary congenital glaucoma in humans and mice due to failure of SC development. Here, we describe a novel approach to enhance canal formation in these animals by deleting a single allele of the gene encoding the phosphatase PTPRB during development. Compared to <italic>Tek</italic> haploinsufficient mice, which exhibit elevated IOP and loss of retinal ganglion cells, <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>+/- </sup>mice have elevated TEK phosphorylation, which allows normal SC development and prevents ocular hypertension and RGC loss. These studies provide evidence that PTPRB is an important regulator of TEK signaling in the aqueous humor outflow pathway and identify a new therapeutic target for treatment of glaucoma.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 HL124120</award-id><principal-award-recipient><name><surname>Quaggin</surname><given-names>Susan E</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 EY025799</award-id><principal-award-recipient><name><surname>Quaggin</surname><given-names>Susan E</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30 DK114857</award-id><principal-award-recipient><name><surname>Quaggin</surname><given-names>Susan E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Isabel A Carota, was employed by Eli Lilly and Company during the time of study completion and manuscript preparation.</p></fn><fn fn-type="conflict" id="conf3"><p>Dietmar Vestweber, is a scientific advisory board member of Aerpio Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf4"><p>Susan E Quaggin, has applied for patents related to therapeutic targeting of the ANGPT-TEK pathway in ocular hypertension and glaucoma and receives research support, owns stock in and is a director of Mannin Research.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the ARVO guidelines for care and use of vertebrate research subjects in eye research. All animal experiments were approved by the Animal Care Committee at the Center for Comparative Medicine of Northwestern University (Evanston, Illinois, USA) under animal protocols IS00002777, IS00006571 and IS00003091.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data described have been included in the manuscript. No data sets were generated during the course of this study.</p></sec><supplementary-material><ext-link xlink:href="elife-48474-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>